Kamada Secures $10-$14 Million Extension for Canadian Plasma-Derived Products Supply

Reuters

Dec 18, 2025

Kamada Secures $10-$14 Million Extension for Canadian Plasma-Derived Products Supply

Kamada Ltd. has announced that it has been awarded a two-year extension of an existing supply tender from Canadian Blood Services (CBS) for four specialty plasma-derived products: WINRHO®, HEPAGAM®, CYTOGAM®, and VARIZIG®. The extension is valued at $10-$14 million and will secure ongoing sales of approximately $5.0-$7.0 million per year between the second quarter of 2026 and the first quarter of 2028. All four products are approved by Health Canada and the U.S. Food and Drug Administration. Kamada also continues to supply its KAMRAB® anti-Rabies Immunoglobulin product and GLASSIA® AAT product in Canada. The company has reiterated its 2025 full-year revenue guidance of $178 million to $182 million and adjusted EBITDA guidance of $40 million to $44 million, and projects double-digit growth in revenues and profitability in 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kamada Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-123054), on December 18, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2592084759"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2592084759\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2592084759?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-18 20:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2592084759","market":"us","top_or_hot":-1,"title":"Kamada Secures $10-$14 Million Extension for Canadian Plasma-Derived Products Supply","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Kamada Secures $10-$14 Million Extension for Canadian Plasma-Derived Products Supply\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/KMDA\">Kamada Ltd.</a> has announced that it has been awarded a two-year extension of an existing supply tender from Canadian Blood Services (CBS) for four specialty plasma-derived products: WINRHO®, HEPAGAM®, CYTOGAM®, and VARIZIG®. The extension is valued at $10-$14 million and will secure ongoing sales of approximately $5.0-$7.0 million per year between the second quarter of 2026 and the first quarter of 2028. All four products are approved by Health Canada and the U.S. Food and Drug Administration. Kamada also continues to supply its KAMRAB® anti-Rabies Immunoglobulin product and GLASSIA® AAT product in Canada. The company has reiterated its 2025 full-year revenue guidance of $178 million to $182 million and adjusted EBITDA guidance of $40 million to $44 million, and projects double-digit growth in revenues and profitability in 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kamada Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-123054), on December 18, 2025, and is solely responsible for the information contained therein.</span></i>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kamada Secures $10-$14 Million Extension for Canadian Plasma-Derived Products Supply</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKamada Secures $10-$14 Million Extension for Canadian Plasma-Derived Products Supply\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-18 20:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Kamada Secures $10-$14 Million Extension for Canadian Plasma-Derived Products Supply\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/KMDA\">Kamada Ltd.</a> has announced that it has been awarded a two-year extension of an existing supply tender from Canadian Blood Services (CBS) for four specialty plasma-derived products: WINRHO®, HEPAGAM®, CYTOGAM®, and VARIZIG®. The extension is valued at $10-$14 million and will secure ongoing sales of approximately $5.0-$7.0 million per year between the second quarter of 2026 and the first quarter of 2028. All four products are approved by Health Canada and the U.S. Food and Drug Administration. Kamada also continues to supply its KAMRAB® anti-Rabies Immunoglobulin product and GLASSIA® AAT product in Canada. The company has reiterated its 2025 full-year revenue guidance of $178 million to $182 million and adjusted EBITDA guidance of $40 million to $44 million, and projects double-digit growth in revenues and profitability in 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kamada Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-123054), on December 18, 2025, and is solely responsible for the information contained therein.</span></i>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KMDA","symbol_name":"Kamada Ltd.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nNDL5q1jVJ:1","article_id":"2592084759","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2592084759","pubTimestamp":1766059285,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Kamada Ltd. has announced that it has been awarded a two-year extension of an existing supply tender from Canadian Blood Services  for four specialty plasma-derived products: WINRHO, HEPAGAM, CYTOGAM, and VARIZIG. The extension is valued at $10-$14 million and will secure ongoing sales of approximately $5.0-$7.0 million per year between the second quarter of 2026 and the first quarter of 2028. All four products are approved by Health Canada and the U.S. Food and Drug Administration. Kamada also continues to supply its KAMRAB anti-Rabies Immunoglobulin product and GLASSIA AAT product in Canada. The company has reiterated its 2025 full-year revenue guidance of $178 million to $182 million and adjusted EBITDA guidance of $40 million to $44 million, and projects double-digit growth in revenues and profitability in 2026.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"KMDA":"Kamada Ltd.","BK4139":"生物科技"},"translate_title":"Kamada获得加拿大血浆衍生产品供应延期10-1400万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KMDA":0.9},"content_text":"Kamada Secures $10-$14 Million Extension for Canadian Plasma-Derived Products Supply\n    \n\nKamada Ltd. has announced that it has been awarded a two-year extension of an existing supply tender from Canadian Blood Services (CBS) for four specialty plasma-derived products: WINRHO®, HEPAGAM®, CYTOGAM®, and VARIZIG®. The extension is valued at $10-$14 million and will secure ongoing sales of approximately $5.0-$7.0 million per year between the second quarter of 2026 and the first quarter of 2028. All four products are approved by Health Canada and the U.S. Food and Drug Administration. Kamada also continues to supply its KAMRAB® anti-Rabies Immunoglobulin product and GLASSIA® AAT product in Canada. The company has reiterated its 2025 full-year revenue guidance of $178 million to $182 million and adjusted EBITDA guidance of $40 million to $44 million, and projects double-digit growth in revenues and profitability in 2026.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kamada Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-123054), on December 18, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}